New research suggests that an antibody-drug conjugate may offer practice-changing, patient-friendly treatment of blastic ...

Only 6 percent of patients carried a concerning DPYD variant, but nearly two-thirds of them were later hospitalized after ...

The updated data showed positive results and supports the company’s aim to start a Phase 111 trial later this year.

Breast cancer study results impressed at this year’s meeting, but raised new questions. Doctors also wrestled with how best ...

At the heart of innovation is T-win®, a groundbreaking vaccine platform that could change how we treat cancer.

Several oral abstracts presented at the American Society of Clinical Oncology’s annual meeting highlight ongoing research of Keytruda, Opdivo, Tecentriq and more in skin cancer.

Following a supervised exercise lowered people's risk of colon cancer recurrence by 28% in an extensive new clinical trial.

Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control ...

Leaders in oncology share why the American Society of Clinical Oncology (ASCO) meeting remains a top global gathering for breakthroughs, networking, and lifelong learning.

The Trump administration has proposed allocating $4.53 billion for the National Cancer Institute in fiscal year 2026, marking a 37.2% decrease from the $7.22 billion the NCI received in fiscal 2025.

Five early-career Fred Hutch/UW researchers received prestigious Young Investigator Awards from Conquer Cancer, the ASCO Foundation during this year's annual meeting of the American Society of ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.